Replication of a Claims-based Algorithm to Estimate Multiple Sclerosis Disease Severity in a Commercially Insured Population
- PMID: 33032054
- DOI: 10.1016/j.msard.2020.102539
Replication of a Claims-based Algorithm to Estimate Multiple Sclerosis Disease Severity in a Commercially Insured Population
Abstract
Background/objective: Patients with multiple sclerosis (MS) tend to have significantly lower health-related quality of life, increased mortality and morbidity, and increased healthcare costs. The lack of a claims-based algorithm to correctly identify disease severity makes targeted selection of the MS patients for specific interventions an important limitation in real-world MS research.
Methods: Using the Optum claims dataset (2016 -2018), 11,429 persons with MS and >= 24 months of eligibility were identified. A previously developed claims-based algorithm was employed to categorize MS disease severity (low, moderate, high), using MS symptoms and healthcare utilization. Linear regression analysis was used to determine the relationship between disease severity and total cost, a proxy for disease severity. Flexible parametric models were used to determine the risk of 12-month follow-up MS-related relapses and MS-related hospitalizations among the MS disease severity groups.
Results: The risk of both MS-related relapses and MS-related hospitalizations increased as MS disease severity increased. The risk for MS-related relapses was significantly higher in the moderate (HR = 2.43, 95% CI 1.24 -2.64, P < 0.001) and high (HR = 5.97, 95% CI 5.19-6.83, P < 0.001) disease severity groups compared to the low disease severity group. The same trend is observed concerning MS-related hospitalization risk. Both the moderate (HR = 3.16, 95% CI 2.73-3.63, P> 0.001) and high disease severity (HR =12.70, 95% CI 10.57-15.09, P < 0.001) groups had significantly higher risk of MS-related hospitalization compared to the low disease severity group.
Conclusion: The claims-based disease severity algorithm performed well in explaining the total healthcare cost (excluding DMTs). The algorithm-determined disease severity categorization appears consistent with traditional measures of disease severity (MS relapse and hospitalizations). This claims-based algorithm may be a useful tool in determining MS disease severity in claims data.
Keywords: Algorithm; Costs; Disease severity; Multiple sclerosis; Retrospective database.
Copyright © 2020 Elsevier B.V. All rights reserved.
Similar articles
-
Use of a claims-based algorithm to estimate disease severity in the multiple sclerosis Medicare population.Mult Scler Relat Disord. 2021 Apr;49:102741. doi: 10.1016/j.msard.2021.102741. Epub 2021 Jan 7. Mult Scler Relat Disord. 2021. PMID: 33476882
-
Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.Curr Med Res Opin. 2014 Aug;30(8):1461-71. doi: 10.1185/03007995.2014.915802. Epub 2014 May 2. Curr Med Res Opin. 2014. PMID: 24754349
-
Development and validation of a claims-based measure as an indicator for disease status in patients with multiple sclerosis treated with disease-modifying drugs.BMC Neurol. 2017 Jun 5;17(1):106. doi: 10.1186/s12883-017-0887-1. BMC Neurol. 2017. PMID: 28583104 Free PMC article.
-
Mitoxantrone: a review of its use in multiple sclerosis.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review.
-
Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.Mult Scler Relat Disord. 2021 May;50:102778. doi: 10.1016/j.msard.2021.102778. Epub 2021 Jan 28. Mult Scler Relat Disord. 2021. PMID: 33592384 Review.
Cited by
-
Development and Internal Validation of a Disability Algorithm for Multiple Sclerosis in Administrative Data.Front Neurol. 2021 Nov 2;12:754144. doi: 10.3389/fneur.2021.754144. eCollection 2021. Front Neurol. 2021. PMID: 34795632 Free PMC article.
-
Association between multiple sclerosis disease severity and adherence to disease-modifying therapies.J Manag Care Spec Pharm. 2021 Jul;27(7):915-923. doi: 10.18553/jmcp.2021.27.7.915. J Manag Care Spec Pharm. 2021. PMID: 34185555 Free PMC article.
-
Impact of discontinuing disease-modifying therapies on health care utilization among midlife patients with multiple sclerosis in the United States.J Manag Care Spec Pharm. 2024 Nov;30(11):1248-1260. doi: 10.18553/jmcp.2024.30.11.1248. J Manag Care Spec Pharm. 2024. PMID: 39471270 Free PMC article.
-
Claims-based algorithm to estimate the Expanded Disability Status Scale for multiple sclerosis in a German health insurance fund: a validation study using patient medical records.Front Neurol. 2023 Dec 7;14:1253557. doi: 10.3389/fneur.2023.1253557. eCollection 2023. Front Neurol. 2023. PMID: 38130836 Free PMC article.
-
A comparison of clinical, utilization, and cost outcomes between oral treatments for multiple sclerosis.J Manag Care Spec Pharm. 2024 Feb 3;30(2):129-140. doi: 10.18553/jmcp.2024.30.2.129. J Manag Care Spec Pharm. 2024. PMID: 38308623 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical